ArticleMedicines (Basel, Switzerland)2022
The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study.
Article in Medicines (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis of Comparative Studies.Journal of diabetes research · 2026Pooled it
- The Role of SGLT2 Inhibitors in the Prevention of Type 2 Diabetes: A Narrative Review of Current Evidence.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium-glucose cotransporter 2 inhibitor users.British journal of clinical pharmacology · 2026Article
- Effects of empagliflozin and metformin on biofilm formation and pathogenicity factors of urinary Escherichia coli isolates.Folia microbiologica · 2026Article
- Diabetes and hyperglucosuria exacerbate the severity of urinary tract infection caused by uropathogenicInfection and immunity · 2026Article
- Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden.Toxicology reports · 2026Review
- Real-world evidence of urinary tract infections and genital tract infections with sodium-glucose cotransporter-2 inhibitors (SGLT2i) alone or in combination with dipeptidyl peptidase-4 inhibitors (DPP4i) in individuals with type-2 diabetes mellitus in India.BMC endocrine disorders · 2026Observational
- Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors.European journal of clinical pharmacology · 2026Review
- Efficacy and safety of SGLT2 inhibitor empagliflozin in T2DM with established cardiovascular disease: a systematic review and meta-analysis of RCTs.Annals of medicine and surgery (2012) · 2026Article
- Article
- Candida related bladder fungal bezoar causing bladder outlet obstruction: A rare mimicker of mucinous bladder tumour.Urology case reports · 2026Article
- SGLT2 inhibitors do not cause de novo urinary incontinence in diabetic female patients with chronic kidney disease.International urology and nephrology · 2025Article
- SGLT2 Inhibitors and Complicated Urinary Tract Infections: A Rare Case of Emphysematous Pyelonephritis and Subsequent Recurrence Associated With Dapagliflozin Use.Clinical case reports · 2025Article
- SGLT2 Inhibitors and External Genital Infection in Male Patients With Type 2 Diabetes.JAMA network open · 2025Article
- The efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients aged over 80 years with heart failure.ESC heart failure · 2025Article
- Dapagliflozin's Effects on Urinary Albumin and Non-Albumin Proteins in Diabetic and Non-Diabetic Kidney Transplant Recipients.Biomedicines · 2025Article
- Risk of Urinary Tract Infections with Sodium-Glucose Transport Protein-2 Inhibitors in Subpopulations with Abnormal Genitourinary Pathology.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review.Journal of clinical medicine · 2025Review
- SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM.Scientific reports · 2025Observational
- Analysing the influence of dapagliflozin on urinary tract infection vulnerability and kidney injury in mice infected with uropathogenic Escherichia coli.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.